Peak Bio, Inc. (PKBOW)

Overview

Peak Bio, Inc. is a trailblazing clinical-stage biopharmaceutical company with a dedicated focus on pioneering therapeutics for a spectrum of diseases, including inflammatory conditions, cancer, and a range of rare and specialty diseases. Founded in the vibrant tech hub of Pleasanton, California, in 2020, Peak Bio has swiftly emerged as a beacon of innovation and commitment within the biopharmaceutical landscape. Through its advanced clinical studies and research initiatives, the company strives to address the unmet medical needs of patients around the globe, pushing the boundaries of medicine to improve health outcomes and enhance quality of life.

Products and Services

• PHP-303

As Peak Bio's flagship product candidate, PHP-303 is at the forefront of the company's diversified portfolio, currently undergoing rigorous evaluation in a phase 2 clinical study. This groundbreaking compound is designed to treat patients suffering from alpha-1 antitrypsin deficiency and acute respiratory distress syndrome (ARDS). By targeting these critical conditions, PHP-303 exemplifies Peak Bio's commitment to developing innovative therapies that offer hope and relief to individuals facing serious health challenges.

• Trop2 PH1

Another key element within Peak Bio's dynamic array of offerings is Trop2 PH1, an advanced antibody-drug-conjugate specifically engineered for the treatment of solid tumors. This promising therapeutic candidate signifies the company's strides in oncology, aiming to deliver targeted, effective cancer treatments. Trop2 PH1 reflects Peak Bio's dedication to leveraging cutting-edge science and technology in order to bring novel oncological solutions to patients in need.